Celgene (NASDAQ:CELG)

Short Interest Pulls Back in Major Biotechs

The short interest data are out for the most recent settlement date, March 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now

If any sector is offering value in what really appears to be a very overbought stock market, it is pharmaceutical, including biotechnology. Absolutely battered during the election cycle when rhetoric over ...
Read Full Story »

Major Biotechs See a Retreat in Short Interest

The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: American Express, Amgen, Encana, Gilead, Tesla and Many More

Stocks were indicated lower on Thursday ahead of Friday's key payrolls and unemployment report. The European Central Bank maintained rates at 0.00%. Now that the bull market is officially eight years ...
Read Full Story »
Pills and tablets

Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy

Despite the incredible market rally since the election of Donald Trump, not all sectors have responded with the same gusto. One that has lagged some is biotech, and while the ...
Read Full Story »
biotech word cloud

Short Sellers Hike Their Bets in Major Biotechs

The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Exit

Is There More Than Meets the Eye on Celgene’s President, COO Retirement?

Celgene Corp. (NASDAQ: CELG) had seen endless growth and a major stock acceleration in prior years. But that was then, and Wall Street only cares about the upside of the ...
Read Full Story »
automatic inspection machine

Large Cap Biotech Stocks to Buy May Be the Cheapest in Years

Almost every asset class is overbought now, and the few that aren’t — with the exception of one — have good reasons. Utilities and other income proxy stocks that were big in ...
Read Full Story »
Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
research

4 Top Biotech Stocks With Big Upcoming Catalysts

In the world of biotech investing, there are some surefire ways for stocks to move. Pipeline announcements, clinical data and regulatory approval all can move the needle as catalysts for ...
Read Full Story »
biotech word cloud

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, January 13. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with ...
Read Full Story »
Good heart health

What to Expect From Major Health Care Stocks Reporting This Week

As January comes to a close, we are in the heart of earnings season, when most companies report and set a direction for the market. Dow 20,000 has been reached but ...
Read Full Story »
research

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

While the run since the Trump election and now the inauguration has been solid, there are some storm clouds on the horizon. Volatility has drifted to historic lows, while price-to-earnings ...
Read Full Story »
research

Biotech Short Sellers Run for Cover

The short interest data are out for the most recent settlement date, December 30. Generally speaking, companies within the biotech industry are considered to have a riskier group of stocks, ...
Read Full Story »
Test tubes

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Needless to say, the past two years have been rough on biotech. So rough in fact, that a basket of the largest capitalization stocks now trades with a price-to-earnings growth ...
Read Full Story »